Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Advanced Rare Cancers
NCT04969887Phase 2Active, not recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in biliary tract cancer (BTC), Neuroendocrine Neoplasm (NEN), female reproductive system neoplasm, solid tumor, sponsored by Olivia Newton-John Cancer Research Institute. Started Aug 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
biliary tract cancer (BTC)Neuroendocrine Neoplasm (NEN)female reproductive system neoplasmsolid tumor
Beyond the preview
Go deeper on NCT04969887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969887.